Evidence map›Paper›PMID 31142671›Full record

ArticleJournal of virology2019

Cytomegalovirus Evades TRAIL-Mediated Innate Lymphoid Cell 1 Defenses.

Gaelle Picarda, Raima Ghosh, Bryan McDonald, Shilpi Verma, Nicolas Thiault, Rachid El Morabiti, Thomas S Griffith, Chris A Benedict

Abstract read
In one paragraph

Article in Journal of virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gaelle PicardaDivision of Immune Regulation, La Jolla Institute for Immunology, La Jolla, California, USA.
Raima GhoshDivision of Immune Regulation, La Jolla Institute for Immunology, La Jolla, California, USA.
Bryan McDonaldDivision of Immune Regulation, La Jolla Institute for Immunology, La Jolla, California, USA.
Shilpi VermaDivision of Immune Regulation, La Jolla Institute for Immunology, La Jolla, California, USA.
Nicolas ThiaultDivision of Developmental Immunology, La Jolla Institute for Immunology, La Jolla, California, USA.
Rachid El MorabitiDivision of Immune Regulation, La Jolla Institute for Immunology, La Jolla, California, USA.
Thomas S GriffithDepartment of Urology, Masonic Cancer Center, Center for Immunology, University of Minnesota, Minneapolis, Minnesota, USA.
Chris A BenedictDivision of Immune Regulation, La Jolla Institute for Immunology, La Jolla, California, USA benedict@lji.org.

Funding

The role of TRAIL in immune control of cytomegalovirusR01AI101423 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI BENEDICT, CHRISTOPHER A · 2013 to 2023
$4.6M
CD4 T cell control of cytomegalovirusR01AI139749 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI BENEDICT, CHRISTOPHER A · 2019 to 2023
$3.2M
FACSAria II Cell SorterS10RR027366 · NCRR · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROFT, MICHAEL · 2011 to 2011
$514k
Necroptosis and adaptive immunity to virus infectionR21AI113349 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI BENEDICT, CHRISTOPHER A, UPTON, JASON W · 2016 to 2017
$493k
The role of TRAIL in immune control of cytomegalovirusR56AI101423 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI BENEDICT, CHRISTOPHER A · 2012 to 2012
$435k
NCRR NIH HHS S10 RR027366NIAID NIH HHS R01 AI101423NIAID NIH HHS R01 AI139749NIAID NIH HHS R21 AI113349NIAID NIH HHS R56 AI101423
6 · The paper itself

Abstract

Cytomegalovirus (CMV) establishes a lifelong infection facilitated, in part, by circumventing immune defenses mediated by tumor necrosis factor (TNF)-family cytokines. An example of this is the mouse CMV (MCMV) m166 protein, which restricts expression of the TNF-related apoptosis-inducing ligand (TRAIL) death receptors, promoting early-phase replication. We show here that replication of an MCMV mutant lacking m166 is also severely attenuated during viral persistence in the salivary glands (SG). Depleting group I innate lymphoid cells (ILCs) or infecting

Indexed as

Immunity, InnateLymphocyte SubsetsAnimalsBiomarkersCytomegalovirusCytomegalovirus InfectionsHost-Pathogen InteractionsImmunophenotypingKiller Cells, NaturalLiverMiceMice, KnockoutMuromegalovirusSalivary GlandsTNF-Related Apoptosis-Inducing LigandBiomarkersTNF-Related Apoptosis-Inducing LigandTNFSF10 protein, humangroup I ILCsILC1MCMVNKTRAIL

Identifiers

PMID31142671
PMCPMC6675903

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.